Philippines Diabetes Care Drugs Market Share

Statistics for the 2023 & 2024 Philippines Diabetes Care Drugs market share, created by Mordor Intelligence™ Industry Reports. Philippines Diabetes Care Drugs share report includes a market forecast to 2029 and historical overview. Get a sample of this industry share analysis as a free report PDF download.

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:

Market Share of Philippines Diabetes Care Drugs Industry

The diabetes drugs market is semi-consolidated, with few significant generic players. A few major players, like Novo-Nordisk, Sanofi, AstraZeneca, and Bristol Myers Squibb, dominate the insulin drugs and Sglt-2 drugs market. The market for oral drugs, like Sulfonylureas and Meglitinides, comprises more generic players. The intensity of competition among the players is high, as each player is striving to develop new drugs and offer them at competitive pricing. Furthermore, players are tapping into new markets to increase their market shares, especially in emerging economies where the demand is very high compared to the supply.

Philippines Diabetes Care Drugs Market Leaders

  1. Eli Lilly

  2. Boehringer Ingelheim

  3. Astrazeneca

  4. Sanofi

  5. NovoNordisk

*Disclaimer: Major Players sorted in no particular order

Philippines Diabetes Care Drugs Market Concentration

Philippines Diabetes Care Drugs Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)